CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
15.9894
0.19%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0712
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Cabaletta Bio Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 15.9594
Open* 15.7294
1-Year Change* 224%
Day's Range* 15.1694 - 15.9894
52 wk Range 3.22-19.34
Average Volume (10 days) 807.31K
Average Volume (3 months) 16.73M
Market Cap 755.01M
P/E Ratio -100.00K
Shares Outstanding 42.85M
Revenue N/A
EPS -1.71
Dividend (Yield %) N/A
Beta 2.49
Next Earnings Date Mar 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 15.9594 0.4400 2.84% 15.5194 16.0194 15.0194
Nov 30, 2023 15.9694 1.7000 11.91% 14.2694 16.1494 13.9994
Nov 29, 2023 13.8394 0.3100 2.29% 13.5294 15.6194 13.2794
Nov 28, 2023 13.6594 -4.7700 -25.88% 18.4294 18.7494 9.4894
Nov 27, 2023 18.6294 -0.0700 -0.37% 18.6994 19.0894 18.2994
Nov 24, 2023 18.3194 0.1600 0.88% 18.1594 18.9894 18.0094
Nov 22, 2023 18.3894 1.0300 5.93% 17.3594 18.6694 17.0594
Nov 21, 2023 17.5994 0.4900 2.86% 17.1094 18.2194 17.1094
Nov 20, 2023 17.9294 0.0000 0.00% 17.9294 18.3494 16.8694
Nov 17, 2023 17.9194 0.7400 4.31% 17.1794 18.0494 17.0394
Nov 16, 2023 17.4094 0.1200 0.69% 17.2894 17.4594 16.7294
Nov 15, 2023 17.3394 -0.2300 -1.31% 17.5694 18.3394 17.2094
Nov 14, 2023 17.4394 -0.6100 -3.38% 18.0494 18.2794 17.0894
Nov 13, 2023 17.3694 -0.1000 -0.57% 17.4694 17.7694 16.7294
Nov 10, 2023 17.8894 -0.0500 -0.28% 17.9394 18.7794 17.0694
Nov 9, 2023 17.4494 0.2900 1.69% 17.1594 18.4894 17.0494
Nov 8, 2023 17.1494 0.8300 5.09% 16.3194 18.1694 16.0894
Nov 7, 2023 16.0494 0.7500 4.90% 15.2994 16.3194 14.9694
Nov 6, 2023 15.3094 -0.6600 -4.13% 15.9694 16.0694 14.9694
Nov 3, 2023 15.9594 0.3300 2.11% 15.6294 16.3694 15.5094

Cabaletta Bio, Inc. Events

Time (UTC) Country Event
Thursday, March 14, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Cabaletta Bio Inc Earnings Release
Q4 2023 Cabaletta Bio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 54.139 46.313 33.833 18.683 6.193
Selling/General/Admin. Expenses, Total 14.839 13.819 12.457 7.012 1.726
Research & Development 39.3 32.494 21.376 11.671 4.467
Operating Income -54.139 -46.313 -33.833 -18.683 -6.193
Interest Income (Expense), Net Non-Operating 1.164 0.024 0.494 1.74 0.235
Other, Net 0 -6.244
Net Income Before Taxes -52.975 -46.289 -33.339 -16.943 -12.202
Net Income After Taxes -52.975 -46.289 -33.339 -16.943 -12.202
Net Income Before Extra. Items -52.975 -46.289 -33.339 -16.943 -12.202
Net Income -52.975 -46.289 -33.339 -16.943 -12.202
Income Available to Common Excl. Extra. Items -52.975 -46.289 -33.339 -22.269 -12.202
Income Available to Common Incl. Extra. Items -52.975 -46.289 -33.339 -22.269 -12.202
Diluted Net Income -52.975 -46.289 -33.339 -22.269 -12.202
Diluted Weighted Average Shares 29.3429 25.7373 23.1452 24.034 22.5529
Diluted EPS Excluding Extraordinary Items -1.80538 -1.79852 -1.44043 -0.92656 -0.54104
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -1.80538 -1.79852 -1.44043 -0.92656 -0.54104
Total Adjustments to Net Income 0 -5.326
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 15.89 16.956 16.302 11.778 13.06
Selling/General/Admin. Expenses, Total 4.093 4.521 3.902 3.562 3.546
Research & Development 11.797 12.435 12.4 8.216 9.514
Operating Income -15.89 -16.956 -16.302 -11.778 -13.06
Interest Income (Expense), Net Non-Operating 1.403 1.102 0.61 0.351 0.15
Net Income Before Taxes -14.487 -15.854 -15.692 -11.427 -12.91
Net Income After Taxes -14.487 -15.854 -15.692 -11.427 -12.91
Net Income Before Extra. Items -14.487 -15.854 -15.692 -11.427 -12.91
Net Income -14.487 -15.854 -15.692 -11.427 -12.91
Income Available to Common Excl. Extra. Items -14.487 -15.854 -15.692 -11.427 -12.91
Income Available to Common Incl. Extra. Items -14.487 -15.854 -15.692 -11.427 -12.91
Diluted Net Income -14.487 -15.854 -15.692 -11.427 -12.91
Diluted Weighted Average Shares 39.1728 35.4492 30.4136 29.014 28.9869
Diluted EPS Excluding Extraordinary Items -0.36982 -0.44723 -0.51595 -0.39384 -0.44537
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.36982 -0.44723 -0.51595 -0.39384 -0.44537
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 108.834 124.541 113.535 140.552 33.994
Cash and Short Term Investments 106.547 122.222 108.662 136.204 33.017
Cash & Equivalents 81.607 122.222 101.429 136.204 33.017
Prepaid Expenses 2.287 2.319 4.873 4.348 0.977
Total Assets 116.968 126.336 114.724 141.468 34.174
Other Long Term Assets, Total 0.565 0.357 0.299 0.101 0.18
Total Current Liabilities 9.489 8.38 5.18 3.147 0.943
Accounts Payable 2.463 2.333 1.243 0.92 0.603
Accrued Expenses 5.694 2.977 2.445 1.522 0.121
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.332 3.07 1.492 0.705 0.219
Total Liabilities 12.448 8.38 5.18 3.147 0.943
Total Long Term Debt 0 0 0 0 0
Total Equity 104.52 117.956 109.544 138.321 33.231
Redeemable Preferred Stock 0 0 0 0 43.921
Common Stock 0.00029 0.00029 0.00024 0.00024 0
Additional Paid-In Capital 270.129 230.543 175.836 171.28 1.762
Retained Earnings (Accumulated Deficit) -165.562 -112.587 -66.298 -32.959 -12.452
Total Liabilities & Shareholders’ Equity 116.968 126.336 114.724 141.468 34.174
Total Common Shares Outstanding 29.4451 28.9271 24.0628 24.034 22.5529
Property/Plant/Equipment, Total - Net 7.569 1.438 0.89 0.815
Other Equity, Total -0.04729 -0.00029 0.00576 -0.00024
Short Term Investments 24.94 0 7.233
Property/Plant/Equipment, Total - Gross 9.938 2.629 1.348
Accumulated Depreciation, Total -2.369 -1.191 -0.458
Other Liabilities, Total 2.959
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 166.178 177.572 95.734 108.834 88.175
Cash and Short Term Investments 164.391 176.328 93.845 106.547 85.895
Cash & Equivalents 115.501 128.072 93.845 81.607 61.163
Short Term Investments 48.89 48.256 0 24.94 24.732
Prepaid Expenses 1.787 1.244 1.889 2.287 2.28
Total Assets 173.287 184.637 103.447 116.968 91.675
Property/Plant/Equipment, Total - Net 6.125 6.38 7.132 7.569 2.811
Other Long Term Assets, Total 0.984 0.685 0.581 0.565 0.689
Total Current Liabilities 10.616 8.482 9.305 9.489 5.801
Accounts Payable 3.62 2.341 3.955 2.463 1.333
Accrued Expenses 5.632 4.157 3.176 5.694 2.268
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.364 1.984 2.174 1.332 2.2
Total Liabilities 12.364 10.496 11.796 12.448 5.801
Total Long Term Debt 0 0 0 0 0
Total Equity 160.923 174.141 91.651 104.52 85.874
Common Stock 0.00042 0.00039 0.00031 0.00029 0.00029
Additional Paid-In Capital 373.295 370.047 273.067 270.129 235.953
Retained Earnings (Accumulated Deficit) -212.351 -195.903 -181.416 -165.562 -149.87
Other Equity, Total -0.02142 -0.00339 -0.00031 -0.04729 -0.20929
Total Liabilities & Shareholders’ Equity 173.287 184.637 103.447 116.968 91.675
Total Common Shares Outstanding 41.6602 39.7937 31.341 29.4451 29.014
Redeemable Preferred Stock 0 0 0 0
Other Liabilities, Total 1.748 2.014 2.491 2.959
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -52.975 -46.289 -33.339 -16.943 -12.202
Cash From Operating Activities -46.38 -34.109 -26.77 -16.045 -4.661
Non-Cash Items 9.716 5.866 4.507 2.3 8.005
Changes in Working Capital -4.299 5.581 1.708 -1.506 -0.464
Cash From Financing Activities 32.982 48.903 -0.024 119.925 37.677
Issuance (Retirement) of Stock, Net 32.982 48.903 -0.024 119.925 37.677
Net Change in Cash -40.615 20.793 -34.775 103.187 33.016
Cash From Operating Activities 1.178 0.733 0.354 0.104
Cash From Investing Activities -27.217 5.999 -7.981 -0.693
Capital Expenditures -2.453 -1.166 -0.635 -0.693
Other Investing Cash Flow Items, Total -24.764 7.165 -7.346
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -15.854 -52.975 -37.283 -25.856 -12.946
Cash From Operating Activities -12.608 -46.38 -34.249 -24.335 -12.809
Cash From Operating Activities 0.365 1.178 0.82 0.457 0.219
Non-Cash Items 3.023 9.716 5.142 3.466 1.763
Changes in Working Capital -0.142 -4.299 -2.928 -2.402 -1.845
Cash From Investing Activities 24.62 -27.217 -26.901 -50.809 -49.911
Capital Expenditures -0.38 -2.453 -2.137 -1.045 -0.147
Other Investing Cash Flow Items, Total 25 -24.764 -24.764 -49.764 -49.764
Cash From Financing Activities 0.226 32.982 0.091 0.091 0.051
Issuance (Retirement) of Stock, Net 0.458 32.982 0.091 0.091 0.051
Net Change in Cash 12.238 -40.615 -61.059 -75.053 -62.669
Financing Cash Flow Items -0.232
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fred Alger Management, LLC Investment Advisor/Hedge Fund 11.4882 4572886 557576 2023-06-30 MED
Adage Capital Management, L.P. Hedge Fund 8.2066 3266645 725000 2023-06-30 LOW
Commodore Capital LP Hedge Fund 5.9495 2368186 533186 2023-06-30 MED
Deerfield Management Company, L.P. Hedge Fund 5.879 2340118 0 2023-06-30 MED
Cormorant Asset Management, LP Hedge Fund 5.5816 2221739 400000 2023-06-30 LOW
Lynx1 Capital Advisors LLC Investment Advisor 5.4802 2181377 -273250 2023-06-30 MED
Bain Capital Life Sciences Investors, LLC Investment Advisor 5.0245 2000000 0 2023-06-30 LOW
VR Adviser, LLC Venture Capital 4.9573 1973251 0 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.3249 1721512 607569 2023-06-30 LOW
Baker Bros. Advisors LP Hedge Fund 4.0045 1594000 250000 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.9809 1584584 1363780 2023-06-30 LOW
Perceptive Advisors LLC Private Equity 3.8814 1545000 820223 2023-06-30 MED
Redmile Group, LLC Investment Advisor/Hedge Fund 3.4425 1370299 1096047 2023-06-30 LOW
Nichtberger (Steven) Individual Investor 3.3902 1349483 0 2023-04-03 LOW
Jennison Associates LLC Investment Advisor/Hedge Fund 2.9659 1180564 400000 2023-06-30 LOW
Invesco Capital Management LLC Investment Advisor 2.1219 844621 844621 2023-06-30 LOW
Boxer Capital, L.L.C. Hedge Fund 1.3566 540000 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.263 502727 282877 2023-06-30 LOW
Blackstone Alternative Asset Management, L.P. Investment Advisor/Hedge Fund 1.2531 498779 498779 2023-06-30 HIGH
TCG Crossover Management, LLC Investment Advisor 1.2229 486795 0 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cabaletta Bio, Inc. Company profile

About Cabaletta Bio Inc

Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.

Industry: Bio Therapeutic Drugs

2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

US100

15,819.90 Price
-1.110% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

41,900.40 Price
+5.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.63 Price
-0.120% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

73.39 Price
-1.480% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee -0.0019%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading